The 5α-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population

European Urology

Volumn 48, Issue 4, 2005, Pages 679-685

  Giwercman, Yvonne L ^a   Abrahamsson, Per Anders ^a   Giwercman, Aleksander ^a   Gadaleanu, Virgil ^a   Ahlgren, Göran ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 reductase; Androgen receptor; Polymorphism; Prostate cancer

Indexed keywords

5ALPHA REDUCTASE 2; ANDROGEN RECEPTOR; REPETITIVE DNA; SEX HORMONE; STEROID 5ALPHA REDUCTASE; UNCLASSIFIED DRUG; ALANINE; ANDROSTANOLONE; ARGININE; GLUTAMINE; LEUCINE; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THREONINE; TUMOR MARKER; VALINE;

AGED; ALLELE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; DNA POLYMORPHISM; ENZYME ACTIVITY; GENE ACTIVITY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SOLDIER; BLOOD; CASE CONTROL STUDY; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; LONG TERMINAL REPEAT; METABOLISM; MIDDLE AGED; POINT MUTATION; PROSTATE TUMOR; RISK FACTOR; SWEDEN;

AGED; ALANINE; ALLELES; ARGININE; CASE-CONTROL STUDIES; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTAMINE; HUMANS; LEUCINE; LUTEINIZING HORMONE; MALE; MIDDLE AGED; POINT MUTATION; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; SWEDEN; TERMINAL REPEAT SEQUENCES; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; THREONINE; TUMOR MARKERS, BIOLOGICAL; VALINE;

EID: 24644440563     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.06.011     Document Type: Article

References (38)

1. L.N. Kolonel, D. Altshuler, and B.E. Henderson The multiethnic cohort study: exploring genes, lifestyle and cancer risk Nat Rev Cancer 4 2004 519 527
2. E.D. Crawford Epidemiology of prostate cancer Urology 62 2003 3 12
3. A.E. Thigpen, R.I. Silver, J.M. Guileyardo, M.L. Casey, J.D. McConnell, and D.W. Russell Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression J Clin Invest 2 1993 903 910
4. E.D. Crawford Epidemiology of prostate cancer Urology 62 2003 3 12
5. N. Makridakis, A. Akalu, and J.K. Reichardt Identification and characterization of somatic steroid 5 alpha-reductase (SRD5A2) mutations in human prostate cancer tissue Oncogene 23 2004 7399 7405
6. N.M. Makridakis, E. di Salle, and J.K. Reichardt Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II Pharmacogenetics 10 2000 407 413
7. N.M. Makridakis, E. di Salle, and J.K. Reichardt Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II Pharmacogenetics 10 2000 407 413
8. E.D. Crawford Epidemiology of prostate cancer Urology 62 2003 3 12
9. G.H. Sinnecker, O. Hiort, L. Dibbelt, N. Albers, H.G. Dorr, and H. Hauss Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency Am J Med Genet 63 1996 223 230
10. A.W. Hsing, C. Chen, A.P. Chokkalingam, Y.T. Gao, D.A. Dightman, and H.T. Nguyen Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study Cancer Epidemiol Biomarkers Prev 10 2001 1077 1082
11. M. Algarté-Génin, O. Cussenot, and P. Costa Prevention of prostate cancer by androgens: experimental paradox or clinical reality Eur Urol 46 2004 285 295
12. D.B. Lubahn, D.R. Joseph, M. Sar, J. Tan, H.N. Higgs, and R.E. Larson The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate Mol Endocrinol 2 1988 1265 1275
13. H.F.B.M. Sleddens, B.A. Oostra, A.O. Brinkmann, and J. Trapman Trinucleotide repeat polymorphism in the androgen receptor gene Nucleic Acids Res 20 1992 1427
14. T. Gao, M. Marcelli, and M.J. McPhaul Transcriptional activation and transient expression of the human androgen receptor J Steroid Biochem Mol Biol 59 1996 9 20
15. N.L. Chamberlain, E.D. Driver, and R.L. Miesfeld The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function Nucleic Acids Res 22 1994 3181 3186
16. E. Giovannucci, M.J. Stampfer, K. Krithivas, M. Brown, A. Brufsky, and J. Talcott The CAG repeat within the androgen receptor gene and its relationship to prostate cancer Proc Natl Acad Sci 94 1997 3320 3323
17. J.M. Hakimi, M.P. Schoenberg, R.H. Rondinelli, S. Piantadosi, and E.R. Barrack Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer Clin Cancer Res 3 1997 1599 1608
18. J. Richthoff, L. Rylander, L. Hagmar, J. Malm, and A. Giwercman Higher sperm counts in Southern Sweden compared with Denmark Hum Reprod 17 2002 2468 2473
19. K.B. Lundin, A. Giwercman, J. Richthoff, P-A. Abrahamsson, and Y.L. Giwercman No association between mutations in the human androgen receptor GGN repeat and inter-sex conditions Mol Hum Reprod 9 2003 375 379
20. C. Ntais, A. Polycarpou, and J.P. Ioannidis SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis Cancer Epidemiol Biomarkers Prev 12 2003 618 624
21. T. Soderstrom, M. Wadelius, S.O. Andersson, J.E. Johansson, S. Johansson, and F. Granath 5 alpha-reductase 2 polymorphisms as risk factors in prostate cancer Pharmacogenetics 12 2002 307 312
22. J.M. Jaffe, S.B. Malkowicz, A.H. Walker, S. MacBride, R. Peschel, and J. Tomaszewski Association of SRD5A2 genotype and pathological characteristics of prostate tumors Cancer Res 60 2000 1626 1630
23. A.G. Latil, R. Azzouzi, G.S. Cancel, E.C. Guillaume, B. Cochan-Priollet, and P.L. Berthon Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways Cancer 92 2001 1130 1137
24. N. Mononen, T. Ikonen, K. Syrjakoski, M. Matikainen, J. Schleutker, and T.L. Tammela A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland Br J Cancer 84 2001 1344 1347
25. G. Schatzl, S. Madersbacher, A. Gsur, M. Preyer, G. Haidinger, and A. Haitel Association of polymorphisms within androgen receptor, 5 alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men Prostate 52 2002 130 138
26. N.M. Makridakis, E. di Salle, and J.K. Reichardt Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II Pharmacogenetics 10 2000 407 413
27. N.M. Makridakis, E. di Salle, and J.K. Reichardt Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II Pharmacogenetics 10 2000 407 413
28. O. Bratt, Å. Borg, U. Kristoffersson, R. Lundgren, O.X. Zhang, and H. Olsson CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk Br J Cancer 4 1999 672 676
29. R.A. Irvine, M.C. Yu, R.K. Ross, and G.A. Coetzee The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer Cancer Res 54 1994 2861 2864
30. L. Correa-Cerro, G. Wöhr, J. Häussler, P. Berthon, E. Drelon, and P. Mangin (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population Eur J Hum Genet 7 1999 357 362
31. S.M. Edwards, M.D. Badzioch, R. Minter, R. Hamoudi, N. Collins, and A. Ardern-Jones Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival Int J Cancer 84 1999 458 465
32. J.L. Stanford, J.J. Just, M. Gibbs, K.G. Wicklund, C.L. Neal, and B.A. Blumenstein Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk Cancer Res 57 1997 1194 1198
33. S.M. Edwards, M.D. Badzioch, R. Minter, R. Hamoudi, N. Collins, and A. Ardern-Jones Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival Int J Cancer 84 1999 458 465
34. S.M. Edwards, M.D. Badzioch, R. Minter, R. Hamoudi, N. Collins, and A. Ardern-Jones Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival Int J Cancer 84 1999 458 465
35. D. Ding, M. Menon, G.P. Reddy, and E.R. Barrack Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action Prostate 62 2005 133 139
36. E.A. Platz, E. Giovannucci, D.M. Dahl, K. Krithivas, C.H. Hennekens, and M. Brown The androgen receptor gene GGN microsatellite and prostate cancer risk Cancer Epidemiol Biomarkers Prev 7 1998 379 384
37. S.M. Edwards, M.D. Badzioch, R. Minter, R. Hamoudi, N. Collins, and A. Ardern-Jones Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival Int J Cancer 84 1999 458 465
38. M.A. Hoffman, W.C. Dewolf, and A. Morgentaler Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 2000 824 827